Spelling suggestions: "subject:"pharmacology."" "subject:"pharmacologyc.""
211 |
Myocardial effects of caeruleinLee, Wendy W. January 1972 (has links)
No description available.
|
212 |
The interaction between monoamine oxidase inhibitors and meperidineZorychta, Edith A. January 1971 (has links)
No description available.
|
213 |
The unity or multiplicity of the autacoids responsible for the pressor, oxytocic, and renal activities of the posterior lobe of the pituitary gland.Draper, William B. January 1926 (has links)
No description available.
|
214 |
The influence of drugs affecting cardiac adrenergic mechanisms on the movement of radioactive noradrenaline in the perfused heart.Agrawal, Krishan K. January 1965 (has links)
No description available.
|
215 |
The effect of phenelzine on the pharmacology and metabolism of ethanolWade, Daniel J. January 1968 (has links)
No description available.
|
216 |
The role of adrenergic nervous system in hypertension and in the antihypertensive action of methyldopaAyitey-Smith, Edward January 1968 (has links)
No description available.
|
217 |
A comparison of riluzole and edaravone for the treatment of amyotrophic lateral sclerosisRodriguez, Mark 11 February 2022 (has links)
The exact mechanism for the pathogenesis of amyotrophic lateral sclerosis (ALS) is not known. However, a number of causes have been suggested in contributing to the pathology of ALS, including oxidative stress, excitotoxicity, mitochondrial dysfunction, aberrant protein accumulation, imbalance in calcium homeostasis, and inflammatory responses. ALS is either sporadic or familial. A number of mutations in genes have been associated with the familial form: superoxide dismutase 1 (SOD1), transactive response DNA-binding protein (TARDBP), chromosome 9 open reading frame 72 (C9ORF72), and fused in sarcoma/translated in liposarcoma (FUS/TLS). In the United States, the two Food and Drug Administration (FDA)-approved drugs for the treatment of ALS are riluzole and edaravone. Riluzole participates in glutamatergic transmission and has been previously shown to decrease excitotoxicity. Edaravone is a radical scavenger that decreases the generation of reactive oxygen species (ROS). In this thesis, clinical trials and scientific studies involving riluzole and edaravone were analyzed to compare the efficacy of these two drugs. In clinical trials, riluzole appears to prolong life in the early stages of ALS, whereas edaravone appears to only slow symptom progression. Making a decision between these two medications involves considering how each one exerts its effects as well as the efficacy of each one in clinical trials.
|
218 |
An investigation of privileged substructural motifs as templates for the discovery and design of chloroquine-resistance reversal agentsYeh, Susan January 2005 (has links)
Includes bibliographical references (leaves 152-165).
|
219 |
Isolation and characterisation of two antiplasmodial diterpenes from Harpagophytum procumbens (Devil's Claw) and chemical modification of a related analogueClarkson, Cailean January 2002 (has links)
Bibliography: leaves 153-171.
|
220 |
Identification and Characterization of A Zebrafish Glutathione S-Transferase PiAbunnaja, Maryam 20 May 2013 (has links)
No description available.
|
Page generated in 0.0467 seconds